STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 132169

TO:	From:
TO: Carlos Azpuru Location: rem/4d85/7c70 Art Unit: 1615 Thursday, September 23, 2004 Case Serial Number: 10/070244	From: Mary Hale Location: Biotech/Chem Library Rem 1D86 Phone: 2-2507 Mary.Hale@uspto.gov

Search Notes

Searched Inventor and keywords.

Polymer structure too broad.

Sorry for the delay. MHale

Azapure

```
=> e trifusal/cn 5
E1            1     TRIFURYL BORATE/CN
E2            1     TRIFURYLIMIDAZOLINE/CN
E3            0 --> TRIFUSAL/CN
E4            1     TRIGADOLEIN/CN
E5            1     TRIGADOLINIUM TETRASELENIDE/CN

=> e htb/cn 5
E1            1     HTAQ 70P/CN
E2            1     HTAR SUPPRESSOR PROTEIN (NITROSOMONAS EUROPAEA STRAIN ATCC 1
                    9718 GENE SOHA,PRLF)/CN
E3            1 --> HTB/CN
E4            1     HTB 1/CN
E5            1     HTB 3/CN

=> s e3;d ide can
L1            1 HTB/CN


L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   674303-08-3  REGISTRY
CN   1-Propanaminium, N,N,N-trimethyl-3-[(1-oxo-2-propenyl)amino]-, chloride,
     polymer with 2-propenamide, 2-propenoic acid and sodium
     2-propene-1-sulfonate (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   HTB
MF   (C9 H19 N2 O . C3 H6 O3 S . C3 H5 N O . C3 H4 O2 . Cl . Na)x
CI   PMS
PCT  Polyacrylic, Polyvinyl
SR   CA
LC   STN Files:   CA, CAPLUS
DT.CA  CAplus document type:  Journal
RL.NP  Roles from non-patents:  USES (Uses)

     CM   1

     CRN  45021-77-0  (45021-76-9)
     CMF  C9 H19 N2 O . Cl
```



```
     CM   2

     CRN  2495-39-8  (1606-80-0)
     CMF  C3 H6 O3 S . Na
```

Searched by: Mary Hale 571-272-2507 REM 1D86



CM 3

CRN 79-10-7
CMF C3 H4 O2



CM 4

CRN 79-06-1
CMF C3 H5 N O



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:273157

```
=> e 328-90-5/rn 5
E1            1     328-88-1/RN
E2            1     328-89-2/RN
E3            1 --> 328-90-5/RN
E4            1     328-91-6/RN
E5            1     328-92-7/RN

=> s e3;d
L2            1 328-90-5/RN
```

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **328-90-5** REGISTRY
CN Benzoic acid, 2-hydroxy-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4-Cresotic acid, α,α,α-trifluoro- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2-Hydroxy-4-(trifluoromethyl)benzoic acid
CN 4-(Trifluoromethyl)salicylic acid
FS 3D CONCORD
MF C8 H5 F3 O3
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,

Searched by: Mary Hale 571-272-2507 REM 1D86

CHEMCATS, IFICDB, IFIPAT, IFIUDB, MEDLINE, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

46 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
46 REFERENCES IN FILE CAPLUS (1907 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> e acrylic monomer/cn 5
E1            1      ACRYLIC METHACRYLIC ANHYDRIDE-BUTYL METHACRYLATE-METHYL METH
                     ACRYLATE COPOLYMER/CN
E2            1      ACRYLIC MICROGEL IN 67271/CN
E3            0 --> ACRYLIC MONOMER/CN
E4            1      ACRYLIC PLASTICS/CN
E5            1      ACRYLIC POLYMER/CN

=> e vinylic monomer/cn 5
E1            1      VINYLHYDROQUINONE-METHYL METHACRYLATE COPOLYMER/CN
E2            1      VINYLHYDROXYLAMINE/CN
E3            0 --> VINYLIC MONOMER/CN
E4            1      VINYLIDENE/CN
E5            1      VINYLIDENE BROMIDE/CN

=> fil medl,hcapl,biosis,embase,wpids;s (?polymer? and (trifusal or htb or 328-90-5
or l1 or l2 or metabolite(5a)trifusal))
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              10.71      11.34

FILE 'MEDLINE' ENTERED AT 10:11:12 ON 23 SEP 2004

FILE 'HCAPLUS' ENTERED AT 10:11:12 ON 23 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:11:12 ON 23 SEP 2004
```

Searched by: Mary Hale 571-272-2507 REM 1D86

FILE 'EMBASE' ENTERED AT 10:11:12 ON 23 SEP 2004

FILE 'WPIDS' ENTERED AT 10:11:12 ON 23 SEP 2004

L3 23 FILE MEDLINE
L4 37 FILE HCAPLUS
L5 32 FILE BIOSIS
L6 19 FILE EMBASE
'RN' IS NOT A VALID FIELD CODE
L7 8 FILE WPIDS

TOTAL FOR ALL FILES
L8 119 (?POLYMER? AND (TRIFUSAL OR HTB OR 328-90-5 OR L1 OR L2 OR METABOLITE(5A) TRIFUSAL))

=> s l8 and (acrylic or vinyl? or monomer? or hydrolysabl?)
L9 0 FILE MEDLINE
L10 6 FILE HCAPLUS
L11 0 FILE BIOSIS
L12 0 FILE EMBASE
L13 3 FILE WPIDS

TOTAL FOR ALL FILES
L14 9 L8 AND (ACRYLIC OR VINYL? OR MONOMER? OR HYDROLYSABL?)

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15 7 DUP REM L14 (2 DUPLICATES REMOVED)

=> d 1-7 cbib abs

L15 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
2003:434626 Document No. 139:22832 One-step process for preparing polyanhydrides. Uhrich, Kathryn E.; Schmeltzer, Robert C.; Anastasion, Theodore James; Pudil, Bryant J.; Wood, Richard D. (Rutgers, the State University of New Jersey, USA). PCT Int. Appl. WO 2003046034 A2 20030605, 58 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US37799 20021125. PRIORITY: US 2001-PV333247 20011123; US 2001-PV333226 20011123.
AB A method for preparing **monomers** of general formula HOCOR1-XR2-XR1COOH which can be **polymerized** to provide a **polymer** that contains therapeutically active compds. is given. Each R1 represents a therapeutically active moiety, X is an ester or amide linkage, and R2 is a linking group. Breakdown of the **polymer** yields the therapeutic agent. The therapeutic agent may be an antiinflammatory, analgesic, anesthetic, antiseptic, or antimicrobial compound

L15 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
2004:12190 Document No. 140:273157 Synthesis and evaluation of a amphoteric

copolymer HTB as drilling fluid additive. Luo, Zhi-hua; Zhang, Yan-fang; Luo, Yao; Zhang, Jian-guo; Zhang, Yi-hua (Department of Chemistry, Jianghan Petroleum University, Jingzhou, 434023, Peop. Rep. China). Huaxue Yu Shengwu Gongcheng, 20(5), 55-56 (Chinese) 2003. CODEN: HYSGAF. ISSN: 1672-5425. Publisher: Huaxue Yu Shengwu Gongcheng Bianjibu.

AB A new amphoteric **copolymer HTB** was synthesized by **copolymn.** of acrylamide (AM), **acrylic** acid (AA), allyl sulfonic acid sodium (AS), acrylamido propane tri-Me ammonium chloride. **Polymerization** conditions such as initiator, pH, **monomer** concentration , **polymerization** temperature were studied. The exptl. results show the **copolymer** possesses fair good drilling fluid performances. The fresh water mud treated by 0.3% **copolymer** keep low filtrate loss after rolling at 180°C in 16 h and adding 20% CaCl2, adding 0.2% the **copolymer**, the inhibitory property is much better than that of 7% KCl.

L15 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:832576 Document No. 137:346197 Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent. Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed (Epigenesis Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2002085309 A2 20021031, 764 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US13143 20020423. PRIORITY: US 2001-PV286036 20010424.

AB This patent relates to a composition comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addition, they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. These agents and the composition and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases associated with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and composition may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in

essential the same manner.

L15 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
2001:185619 Document No. 134:227434 New biocompatible **polymer** systems carrying triflusal or **HTB**. Gallardo Ruiz, Alberto; Rodriguez Crespo, Gema; San Roman del Barrio, Julio (J. Uriach & Cia S.A., Spain). PCT Int. Appl. WO 2001017578 A1 20010315, 43 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Spanish). CODEN: PIXXD2. APPLICATION: WO 2000-ES335 20000901. PRIORITY: ES 1999-2013 19990903.

AB The invention relates to new biocompatible **polymer** systems which carry triflusal or **HTB** and which result from the **polymn**. of a **monomer** A of the **acrylic** or **vinyl** type and carrying triflusal or **HTB**, wherein triflusal or **HTB** are linked to the remainder of the mol. of said **monomer** through an in vivo **hydrolysable** covalent bond and optionally a second **polymerizable monomer** B. These new **polymer** systems are useful as coating for synthetic biomaterials.

L15 ANSWER 5 OF 7 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2001-202772 [20] WPIDS
AB WO 200111050 A UPAB: 20010410
NOVELTY - A nucleic acid (N1) encoding a novel member of the tumor necrosis ligand (TNF) supergene family, designated Fhm, is new.

DETAILED DESCRIPTION - A nucleic acid (N1) encoding a novel member of the tumor necrosis ligand (TNF) supergene family, designated Fhm, is new.

N1 comprises a sequence selected from:

(a) the 819 nucleotide sequence (I) defined in the specification;

(b) a nucleotide sequence encoding the 251 amino acid sequence (II) defined in the specification;

(c) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of (a) or (b), where the encoded polypeptide has the activity of (II);

(d) a nucleotide sequence complementary to any of (a)-(c);

(e) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to (II), where the polypeptide has the activity of (II);

(f) a nucleotide sequence encoding an allelic variant or splice variant of (I), where the encoded polypeptide has the activity of (II);

(g) a nucleotide sequence of (I), or the nucleic acid of (e) or (f) encoding a polypeptide fragment of at least 25 amino acid residues, where the polypeptide has the activity of (II);

(h) a nucleotide sequence of (I), or the nucleic acid of (e), (f) or (g) comprising a fragment of at least 16 nucleotides;

(i) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (e)-(h), where the polypeptide has the activity of (II);

(j) a nucleotide sequence complementary to any of (e)-(g);

(k) a nucleotide sequence encoding (II) with at least one conservative amino acid substitution, insertion, deletion, or a C- and/or N- terminal truncation, where the polypeptide has the activity of (II);

(l) a nucleotide sequence of (k) comprising a fragment of at least about 16 nucleotides;

(m) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (k)-(l), where the

polypeptide has the activity of (II); or

(n) a nucleotide sequence complementary to (k).

INDEPENDENT CLAIMS are also included for the following:

(1) a vector comprising N1;

(2) a host cell comprising the vector of (1);

(3) a method (M1) of producing a Fhm polypeptide comprising culturing the host cell of (2);

(4) a polypeptide produced by the process of (3);

(5) a process for identifying candidate inhibitors or stimulators of Fhm polypeptide activity or production;

(6) an isolated polypeptide (P1) comprising the amino acid sequence of (II);

(7) an isolated polypeptide (P2) comprising the amino acid sequence selected from:

(a) the mature amino acid sequence of (II), comprising a mature amino terminus at residue 1, optionally further comprising an amino-terminal methionine;

(b) an amino acid sequence for an ortholog of (II), where the encoded polypeptide has an activity of (II);

(c) an amino acid sequence that is at least 70 percent identical to the amino acid sequence of (II), where the polypeptide has an activity of (II);

(d) a fragment of (II) comprising at least 25 amino acid residues, where the polypeptide has an activity of (II);

(e) an amino acid sequence for an allelic variant or splice variant of either (II), or at least one of (a)-(c) where the polypeptide has an activity of (II); or

(f) the amino acid sequence of (II) with at least one conservative amino acid substitution, insertion, deletion, or a C- and/or N-terminal truncation, where the polypeptide has an activity of (II);

(8) an isolated polypeptide encoded by N1;

(9) an antibody produced by immunizing an animal with a peptide comprising the sequence of (II);

(10) a monoclonal antibody or its fragment that specifically binds P1 or P2;

(11) a hybridoma that produces a monoclonal antibody that binds to a peptide comprising the sequence of (II);

(12) a method of detecting or quantitating the amount of Fhm in a sample;

(13) a selective binding agent (A1) or its fragment that specifically binds at least one polypeptide;

(14) a selective binding agent (A2) or its fragment comprising at least one complementarity determining region (CDR) with specificity for (II);

(15) a method for treating, preventing, or ameliorating a disease, condition, or disorder, comprising administering to an effective amount of A1;

(16) a selective binding agent produced by immunizing an animal with a polypeptide comprising (II);

(17) a hybridoma that produces a selective binding agent capable of binding P1 or P2;

(18) a polypeptide (P3) comprising a derivative of P1 or P2;

(19) a viral vector comprising N1;

(20) a fusion polypeptide (P4) comprising P1 or P2 fused to a heterologous amino acid sequence;

(21) a method for treating, preventing or ameliorating a medical condition in a mammal resulting from decreased levels of Fhm polypeptide, comprising administering P1, P2 or the polypeptide encoded by N1 to the mammal;

(22) a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject caused by or resulting from abnormal levels of Fhm polypeptide;

(23) a device, comprising cells that secrete P1 or P2, or the Fhm polypeptide;
(24) a method of identifying a compound which binds to a polypeptide;
(25) a method of modulating levels of a polypeptide in an animal, comprising administering N1 to the animal;
(26) a transgenic non-human mammal comprising N1;
(27) a diagnostic reagent comprising a detectably labeled polynucleotide (II), or its fragment, variant or homolog including its allelic variants and spliced variants;
(28) a method (M2) for determine the presence of Fhm nucleic acids in a biological sample;
(29) a method (M3) for detecting the presence of Fhm nucleic acids in a tissue or cellular sample; and
(30) an antagonist of Fhm polypeptide activity.
ACTIVITY - Antiviral; antianemic; immunosuppressive; cytostatic; antimalarial; antidiabetic; cardiant; antibacterial; anoretic.
No biological data given.
MECHANISM OF ACTION - Fhm antagonist; gene therapy.
USE - The Fhm polypeptide and nucleic acid molecules may be used to treat, prevent, ameliorate, diagnose and/or detect TNF-related diseases, e.g. acquired-immunodeficiency syndrome (AIDS), anemia, autoimmune diseases, cachexia, cancer, cerebral malaria, diabetes mellitus, erythryoid sick syndrome, hepatitis, insulin resistance, leprosy, leukemia, lymphoma, meningitis, multiple sclerosis, myocardial ischaemia, obesity, rejection of transplanted organs, rheumatoid arthritis, septic shock syndrome, stroke, adult respiratory distress syndrome and tuberculosis.
Dwg.0/2

L15 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
1991:103864 Document No. 114:103864 Preparation and use of composites swellable by water. Bottiglione, Vincent; Mutschler, Gerard (Intissel S. A., Fr.). Fr. Demande FR 2640547 A1 19900622, 19 pp. (French). CODEN: FRXXBL. APPLICATION: FR 1988-16837 19881220.
AB The title composites, useful in the sealing of cables, agriculture, and medicine, comprise mixts. of H2O-swellable powders and thermally bondable powders between flat, solid supports, ≥1 of which is at least partially soluble in H2O. A suitable composition contained polyester fibers (Grilene **HTB**) 73, poly(**vinylpyrrolidone**) binder 25, and Triton GR5M (wetting agent) 2%.

L15 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
1975:412060 Document No. 83:12060 Jig dyeing of **acrylic** textiles. Ohbayashi, Tsutomu (Mitsubishi Rayon Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 49109688 19741018 Showa, 3 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1973-24043 19730228.
AB Jig dyeing of **acrylic** fiber thick textiles is improved by dyeing the textiles with a dyeing bath containing an organic retarding agent and subsequent dyeing without the organic retarding agent. Thus, a vonnel textile (anacrylonitrile **copolymer** fiber textile) was dyed in a dyeing bath containing Basacryl Blue-GL (I) 1.0, Aizen Cathilon yellow GCLH (II) 0.01, Astrazon Yellow 7GLL (III) 0.05, Catinal **HTB** [55584-68-4] (an organic dyeing retarding agent) 1.5, a nonionic surfactant 0.5, AcOH 0.05, and NaOAc 0.05% (based on textile), washed 4 times with 80° water, and dyed again in a dyeing bath containing I 2.0, II 0.02, III 0.1, AcOH 0.05, NaOAc 0.05, and Na2SO4 10.0% to give a textile dyed in even, deep, and bright shade.

=> s l8 not l14
L16 23 FILE MEDLINE
L17 31 FILE HCAPLUS

Searched by: Mary Hale 571-272-2507 REM 1D86

```
L18          32 FILE BIOSIS
L19          19 FILE EMBASE
L20           5 FILE WPIDS

TOTAL FOR ALL FILES
L21         110 L8 NOT L14

=> dup rem l21
PROCESSING COMPLETED FOR L21
L22          71 DUP REM L21 (39 DUPLICATES REMOVED)

=> s ruiz, a?/au or ruiz a?/in,au;s rodriquez crespo, g?/au or rodriquez crespo
g?/au,in
'IN' IS NOT A VALID FIELD CODE
L23        1059 FILE MEDLINE
L24        1171 FILE HCAPLUS
L25        1011 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L26         904 FILE EMBASE
L27          97 FILE WPIDS

TOTAL FOR ALL FILES
L28        4242 RUIZ, A?/AU OR RUIZ A?/IN,AU


'IN' IS NOT A VALID FIELD CODE
L29           0 FILE MEDLINE
L30           0 FILE HCAPLUS
L31           0 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L32           0 FILE EMBASE
L33           0 FILE WPIDS

TOTAL FOR ALL FILES
L34           0 RODRIQUEZ CRESPO, G?/AU OR RODRIQUEZ CRESPO G?/AU,IN

=> s crespo, g?/au or crespo g?/au,in
'IN' IS NOT A VALID FIELD CODE
L35          39 FILE MEDLINE
L36          29 FILE HCAPLUS
L37          82 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L38          24 FILE EMBASE
L39           3 FILE WPIDS

TOTAL FOR ALL FILES
L40         177 CRESPO, G?/AU OR CRESPO G?/AU,IN

=> s barrio, j?/au or barrio j?/au,in
'IN' IS NOT A VALID FIELD CODE
L41         248 FILE MEDLINE
L42         251 FILE HCAPLUS
L43         398 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L44         213 FILE EMBASE
L45           9 FILE WPIDS

TOTAL FOR ALL FILES
L46        1119 BARRIO, J?/AU OR BARRIO J?/AU,IN

=> s l28 and l40 and l46
L47           0 FILE MEDLINE


Searched by: Mary Hale 571-272-2507 REM 1D86
```

```
L48             0 FILE HCAPLUS
L49             0 FILE BIOSIS
L50             0 FILE EMBASE
L51             0 FILE WPIDS

TOTAL FOR ALL FILES
L52             0 L28 AND L40 AND L46

=> s (l28 or l40 or l46) and l21
L53             0 FILE MEDLINE
L54             0 FILE HCAPLUS
L55             0 FILE BIOSIS
L56             0 FILE EMBASE
L57             0 FILE WPIDS

TOTAL FOR ALL FILES
L58             0 (L28 OR L40 OR L46) AND L21

=> s l21 and biocompatible?
L59             0 FILE MEDLINE
L60             0 FILE HCAPLUS
L61             0 FILE BIOSIS
L62             0 FILE EMBASE
L63             0 FILE WPIDS

TOTAL FOR ALL FILES
L64             0 L21 AND BIOCOMPATIBLE?

=> s biocompatible polymer and (trifusal or htb)
L65             0 FILE MEDLINE
L66             1 FILE HCAPLUS
L67             0 FILE BIOSIS
L68             0 FILE EMBASE
L69             0 FILE WPIDS

TOTAL FOR ALL FILES
L70             1 BIOCOMPATIBLE POLYMER AND (TRIFUSAL OR HTB)

=> s l70 not 121
L71             0 FILE MEDLINE
L72             1 FILE HCAPLUS
L73             0 FILE BIOSIS
L74             0 FILE EMBASE
L75             0 FILE WPIDS

TOTAL FOR ALL FILES
L76             1 L70 NOT L21

=> d cbib abs

L76  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2004 ACS on STN
2001:185619   Document No. 134:227434  New biocompatible
     polymer systems carrying triflusal or HTB.  Gallardo
     Ruiz, Alberto; Rodriguez Crespo, Gema; San Roman del Barrio, Julio (J.
     Uriach & Cia S.A., Spain).  PCT Int. Appl. WO 2001017578 A1 20010315, 43
     pp.  DESIGNATED STATES: W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
     BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE,
     GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
     LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
     SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
     AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI,
     CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL,
```

Searched by: Mary Hale 571-272-2507 REM 1D86

PT, SE, SN, TD, TG. (Spanish). CODEN: PIXXD2. APPLICATION: WO 2000-ES335 20000901. PRIORITY: ES 1999-2013 19990903.

AB The invention relates to new **biocompatible polymer** systems which carry triflusal or **HTB** and which result from the polymerization of a monomer A of the acrylic or vinyl type and carrying triflusal or **HTB**, wherein triflusal or **HTB** are linked to the remainder of the mol. of said monomer through an in vivo hydrolysable covalent bond and optionally a second polymerizable monomer B. These new polymer systems are useful as coating for synthetic biomaterials.

```
=> s gallardo ruiz, a?/au or gallardo ruiz a?/au,in
'IN' IS NOT A VALID FIELD CODE
L77           0 FILE MEDLINE
L78           1 FILE HCAPLUS
L79           0 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L80           0 FILE EMBASE
L81           1 FILE WPIDS

TOTAL FOR ALL FILES
L82           2 GALLARDO RUIZ, A?/AU OR GALLARDO RUIZ A?/AU,IN

=> s rodri!uez crespo, g?/au or rodri!uez crespo g?/au,in
'IN' IS NOT A VALID FIELD CODE
L83           0 FILE MEDLINE
L84           1 FILE HCAPLUS
L85           0 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L86           0 FILE EMBASE
L87           1 FILE WPIDS

TOTAL FOR ALL FILES
L88           2 RODRI!UEZ CRESPO, G?/AU OR RODRI!UEZ CRESPO G?/AU,IN

=> s san roman del barrio, j?/au or san roman del barrio j?/au,in
'IN' IS NOT A VALID FIELD CODE
L89           0 FILE MEDLINE
L90           8 FILE HCAPLUS
L91           1 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L92           1 FILE EMBASE
L93           3 FILE WPIDS

TOTAL FOR ALL FILES
L94          13 SAN ROMAN DEL BARRIO, J?/AU OR SAN ROMAN DEL BARRIO J?/AU,IN

=> s l82 and l88 and l94
L95           0 FILE MEDLINE
L96           1 FILE HCAPLUS
L97           0 FILE BIOSIS
L98           0 FILE EMBASE
L99           1 FILE WPIDS

TOTAL FOR ALL FILES
L100          2 L82 AND L88 AND L94

=> dup rem l100
PROCESSING COMPLETED FOR L100
L101           1 DUP REM L100 (1 DUPLICATE REMOVED)
```

Searched by: Mary Hale 571-272-2507 REM 1D86

```
=> s ?polymer? and (acryl? or vinyl?) and monomer? and (trifusal or htb) and
hydrolys?
L102          0 FILE MEDLINE
L103          1 FILE HCAPLUS
L104          0 FILE BIOSIS
L105          0 FILE EMBASE
L106          0 FILE WPIDS

TOTAL FOR ALL FILES
L107          1 ?POLYMER? AND (ACRYL? OR VINYL?) AND MONOMER? AND (TRIFUSAL OR
                HTB) AND HYDROLYS?

=> d

L107 ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:185619  HCAPLUS
DN   134:227434
TI   New biocompatible polymer systems carrying triflusal or
     HTB
IN   Gallardo Ruiz, Alberto; Rodriguez Crespo, Gema; San Roman del Barrio,
     Julio
PA   J. Uriach & Cia S.A., Spain
SO   PCT Int. Appl., 43 pp.
     CODEN: PIXXD2
DT   Patent
LA   Spanish
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ----------          ----   --------    -------------------      --------
PI   WO 2001017578        A1    20010315    WO 2000-ES335            20000901
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     ES 2154242            A1    20010316    ES 1999-2013             19990903
     ES 2154242            B1    20011016
     EP 1210954            A1    20020605    EP 2000-956531           20000901
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     TR 200200591          T2    20020621    TR 2002-200200591        20000901
     BR 2000013760         A     20020702    BR 2000-13760            20000901
     JP 2003508592         T2    20030304    JP 2001-521365           20000901
     NO 2002001027         A     20020410    NO 2002-1027             20020301
PRAI ES 1999-2013          A     19990903
     WO 2000-ES335         W     20000901
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> log y
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                     59.74       71.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                        ENTRY     SESSION
CA SUBSCRIBER PRICE                                     -4.90       -4.90

Searched by: Mary Hale 571-272-2507 REM 1D86
```

STN INTERNATIONAL LOGOFF AT 10:19:45 ON 23 SEP 2004

Searched by: Mary Hale 571-272-2507 REM 1D86